09/30/2024, 01:32 PM UTC
阿斯利康：不仅仅是安全的赌注Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
1. 阿斯利康的股息增长强劲，自2011年以来股息率持续增长至2.8%，提供可靠的收入和健康的派息比率；2. 在肥胖、心血管和肿瘤学领域拥有强大的研发管线，以及强劲的财务状况，使阿斯利康处于长期增长和稳定的地位；3. 尽管表现不及标普500指数，但阿斯利康专注于高增长领域和有希望的新药，提供了一个引人入胜的增长故事；4. 以合理的估值交易，阿斯利康持续增长的股息和有希望的研发进展使其成为保守投资者的理想选择。1. Amgen's dividend growth is strong with a 2.8% yield and consistent hikes since 2011, providing reliable income and a healthy payout ratio; 2. A robust R&D pipeline in obesity, cardiovascular, and oncology, along with strong financials, positions Amgen for long-term growth and stability; 3. Despite underperforming the S&P 500, Amgen's focus on high-growth areas and promising new drugs offers a compelling growth narrative; 4. Trading at a reasonable valuation, Amgen's combination of consistent dividend growth and promising R&D developments makes it a worthy pick for conservative investors.
---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
